Lapio

Latanoprost, the active ingredient in Lapio, is a prostaglandin analog presented as an eye drop for ocular use. It lowers intra‑ocular pressure by increasing uveoscleral outflow and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Lapio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed under strict quality‑control procedures. GNH USA leverages a global logistics network to ensure timely delivery to qualified healthcare providers.

Latanoprost, marketed as Lapio, is used in the prostaglandin analog class to reduce intraocular pressure in specific eye conditions.

- Open-angle glaucoma: reduces intraocular pressure, helping to preserve visual field and prevent disease progression. - Ocular hypertension: lowers intraocular pressure to reduce the risk of developing glaucoma.

Latanoprost may cause ocular and peri‑ocular reactions, most of which are mild and reversible.

Common Side Effects: - Conjunctival hyperemia: redness of the eye due to increased blood flow. - Increased eyelash growth: longer, thicker, and darker eyelashes. - Iris pigmentation: gradual darkening of the iris, especially in mixed‑color eyes. - Eye irritation or foreign‑body sensation.

Serious or Rare Side Effects: - Uveitis or intraocular inflammation: inflammation inside the eye requiring prompt evaluation. - Severe allergic reaction: swelling, itching, or rash that may need medical attention.

When prescribing Lapio, clinicians should consider several safety and handling measures.

- Baseline assessment: measure intraocular pressure before initiating therapy. - Iris pigmentation: monitor for gradual darkening of the iris, especially in patients with mixed‑color eyes. - Eyelash changes: counsel patients about possible increased length and thickness of eyelashes. - Ocular surface: avoid use in eyes with active inflammation or infection. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at room temperature: keep the bottle in the original packaging, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops: may cause additive ocular irritation. - Recent ocular surgery: increased risk of delayed wound healing; discontinue before surgery.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intraocular pressure reduction may lead to hypotony. - Systemic carbonic anhydrase inhibitors: monitor intraocular pressure for enhanced effect. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular surface irritation.